Black/white breast cancer subtype incidence in men differs from trends in women

byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low

Updated on: December 22,2023 19

Black/white breast cancer subtype incidence in men differs from trends in women

byAmerican Cancer SocietyCredit: CC0 Public DomainIncidence rates for hormone receptor positive (HR+) breast cancers are considerably higher in black men than white men, in stark contrast to low

Updated on:December 22,2023 19

Missing a Rare Cause of Hereditary Cancer

New research fromCedars-Sinai Cancerinvestigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common caus

Updated on: November 07,2023 8

Missing a Rare Cause of Hereditary Cancer

New research fromCedars-Sinai Cancerinvestigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common caus

Updated on:November 07,2023 8

Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA

Updated on: December 21,2023 10

Multisite multiomic analysis reveals diverse resistance mechanisms in end-stage ovarian cancer

by Justin Jackson , Medical XpressThe clinical journey is shown for each patient, in 100 day intervals (x-axis), with the first tick referring to the day of first diagnostic information (surgery or CA

Updated on:December 21,2023 10

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on: December 20,2023 19

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on:December 20,2023 19

Researchers identify potential formula for blood cancer vaccine

byThe Mount Sinai HospitalMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Researchers at the Icahn School of Medicine at

Updated on: December 22,2023 21

Researchers identify potential formula for blood cancer vaccine

byThe Mount Sinai HospitalMicrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0Researchers at the Icahn School of Medicine at

Updated on:December 22,2023 21

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023 76

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023 76

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

byEuropean Society for Medical OncologyFabrice André, oncologist and Professor of Medical Oncology at the Institut Gustave Roussy, Villejuif, France, study author. Credit: © European Society for

Updated on: December 18,2023 13

Targeting specific genomic mutation in breast cancer improves outcomes, first study shows

byEuropean Society for Medical OncologyFabrice André, oncologist and Professor of Medical Oncology at the Institut Gustave Roussy, Villejuif, France, study author. Credit: © European Society for

Updated on:December 18,2023 13

Research reveals how synthesized plankton molecules inhibit cancer proteins

by Justin Jackson , Medical Xpressa, Chemical structure of reported PA and PB (in beige), and the revised structure of PB (in blue) in this work. b, A retrosynthesis targeting a minimally oxidized int

Updated on: October 14,2023 132

Research reveals how synthesized plankton molecules inhibit cancer proteins

by Justin Jackson , Medical Xpressa, Chemical structure of reported PA and PB (in beige), and the revised structure of PB (in blue) in this work. b, A retrosynthesis targeting a minimally oxidized int

Updated on:October 14,2023 132

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on: October 17,2023 63

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Updated on:October 17,2023 63

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on: October 14,2023 189

Newfound mechanism suggests drug combination could starve pancreatic cancer

byNYU Langone HealthPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA new combination of treatments safely decreased growth of pan

Updated on:October 14,2023 189

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on: December 19,2023 12

Targeted lung cancer drug shows promise in phase I/II clinical trial

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainEarly trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain t

Updated on:December 19,2023 12

Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients

by Rutgers Cancer Institute of New JerseyCredit: Pixabay/CC0 Public DomainGenetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, c

Updated on: December 18,2023 11

Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients

by Rutgers Cancer Institute of New JerseyCredit: Pixabay/CC0 Public DomainGenetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, c

Updated on:December 18,2023 11